Jaguar Health reports 2022 prescription revenue up 179% to $11.9M; net loss narrows to $48.4M

Jaguar Health, Inc.

Prescription product net revenue $11.9M for 2022, up 179% YoY from $4.3M in 2021.
Net loss attributable to common shareholders $47.5M ($36.18 per share) vs $52.6M in 2021.
Cash position approximately $15.3M as of March 24, 2023.
Phase 3 OnTarget trial enrollment at ~80%; completion expected in Q2 2023.
Orphan Drug Designation granted for crofelemer for MVID; IND submission planned Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jaguar Health, Inc. reported the year ended December 31, 2022 results: revenue approximately $11.9 million.

Period: the year ended December 31, 2022
Revenue: approximately $11.9 million
Result: reported results

Exact text from the filing

Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-036860

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.